Paratek Pharmaceuticals — FY2020 Earnings Presentation
31 slides from Paratek Pharmaceuticals's earnings presentation, Feb 24, 2021
Slide 1: Financial Results & Corporate Update, 4th Quarter & Full Year 2020
Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. Financial Results & Corporate Update 4th Quarter & Full Year 2020 February 24, 2021 Exhibit 99.2
Slide 2: Earnings Call Agenda
Earnings Call Agenda Fourth Quarter & Full Year 2020 Introduction Ben Strain, Vice President, Investor Relations & Corporate Communications Overview & Financial Highlights Evan Loh, M.D., Chief Executive Officer Q4 & FY 2020 Commercial Highlights Adam Woodrow, President & Chief Commercial Officer Pi
Slide 3: Forward-looking statements
This presentation contains forward-looking statements including statements related to our overall strategy, products, prospects, potential and expected results, including statements about the impact of the COVID-19 pandemic on our revenue projections, access to hospital institutions, supply chain an
Slide 4: Overview & Financial Highlights Q4 & FY 2020
Overview & Financial Highlights Q4 & FY 2020 Evan Loh, M.D. Chief Executive Officer
Slide 5: NUZYRA U.S. Launch Performance
ANTHEM CVS United NUZYRA is on track to have one of the most successful antibiotic launches in the last 5 years. Recent Highlights In face of COVID disruption, NUZYRA generated $38.8 million in 2020, a 237% increase versus prior year 2020 Commercial success has been achieved without any notable expa
Slide 6: Potential $3.7 Billion Addressable Opportunity for NUZYRA
(1) 20% est failures (based on hospital patterns) of first line MRSA treatment. (2) Primary market research (est 18% of hospitalized CABP patients & 16.5% of community CABP patients are “high-risk” and suspected/confirmed to have a resistant pathogen). (3) Cost per course based on health outcome ana
Slide 7: Near-Term Value Creation: 2021 Catalyst-Rich Year
Near-Term Value Creation 2021: A Catalyst-Rich Year Expected 2021 Milestones February 2021: Community Expansion of NUZYRA 1H and 2H 2021: Two BARDA procurements valued at ~$76 Million Q2 2021: FDA decision on the oral-only loading-dose regimen for CABP 1H 2021: Phase 2b Study Initiation in Non-Tuber
Slide 8: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (unaudited) (in thousands, except loss per share data)
Slide 9: Anticipating a Significant Ramp Up in Total Revenue in 2021
Paratek Anticipating a Significant Ramp Up in Total Revenue in 2021 2021 Guidance R&D and SG&A Expense ($ mm) Total Revenue ($ mm)
Slide 10: R-Bridge Royalty and Revenue Interest Backed Loan
Total Value = $60 Million; Non-Recourse to Paratek R-Bridge Royalty and Revenue Interest Backed Loan Received a $60.0 million term loan from R-Bridge that is secured by, and repaid with: Royalties under the license agreement with Zai Labs Revenue interest based on net US sales of NUZYRA in an initia
Slide 11: Balance Sheet Highlights and Cash Runway Guidance
Balance Sheet Highlights and Cash Runway Guidance as of December 31, 2020 Key Metrics 12/31/20 Balance (unaudited) Cash runway projected through 2023 with a pathway to cash flow breakeven.2 Includes common stock issuable under the April 2018 convertible debt offering, options, restricted share units
Slide 12: Commercial Highlights Q4 & FY 2020
Commercial Highlights Q4 & FY 2020 Adam Woodrow President & Chief Commercial Officer
Slide 13: NUZYRA U.S. Launch Performance
ANTHEM CVS United NUZYRA is on track to have one of the most successful antibiotic launches in the last 5 years. Recent Highlights In face of COVID disruption, NUZYRA generated $38.8 million in 2020, a 237% increase versus prior year 2020 Commercial success has been achieved without any notable expa
Slide 14: NUZYRA U.S. Launch: Materially Differentiating From Recent Launches
Value = Oral for Both Go Home (Hospital) and Stay Home (Community) Settings NUZYRA U.S. Launch: Materially Differentiating From Recent Launches Launch Dates: Baxdela Jan 2018 Fetroja Feb 2020 NUZYRA® Feb 2019 Recarbrio Jan 2020 Vabomere Oct 2017 Xenleta Sep 2019 Xerava Oct 2018 Zemdri Jul 2018 Sourc
Slide 15: Strong NUZYRA Payer Coverage
> 90% of Prescriptions filled when written Strong NUZYRA Payer Coverage (~ 300M covered lives as of January 2021) Source: DRG Fingertip Formulary Analytics, January 2021. Over 297 million lives in the U.S. have coverage. ANTHEM CVS United
Slide 16: Community Messaging: Stay Home with NUZYRA
Community Messaging: “Stay Home” with NUZYRA Potential $1.5 Billion Addressable Market Opportunity in ABSSSI Community Messaging* Provides effective & safe once-daily oral dosing Active against Gram-positives, Gram-negatives and drug resistant strains such as MRSA No dosing adjustments required for
Slide 17: U.S. Hospital Targeting Strategy
U.S. Hospital Targeting Strategy Potential $2.6 Billion Addressable Opportunity for NUZYRA Hospital Launch 45 hospital sales specialists Focusing on ‘Early Adopting’ HCPs in ‘high value’ institutions (~600), to drive institutional access Inside Sales Team supplements efforts of Sales Specialists to
Slide 18: U.S. Community Expansion Targeting Strategy
U.S. Community Expansion Targeting Strategy Potential $1.5 Billion Addressable Opportunity for NUZYRA in ABSSSI* 40 community sales specialists Established in February 2021 Focused on geographies with favorable insurance coverage and ID consultant support Accomplished within our current cash runway
Slide 19: Pipeline, Medical & Future Value Drivers
Pipeline, Medical & Future Value Drivers Randy Brenner Chief Development & Regulatory Officer
Slide 20: Project Bioshield: Adding novel antibiotics to the SNS
Project Bioshield: Adding novel antibiotics to the SNS that enhance national security against bioterrorism threats Biothreat agents may be resistant to antibiotics already in the Strategic National Stockpile (SNS) Emerging antibiotic resistance may complicate a response to a public health emergency
Slide 21: First and Only Antibiotic Made in the U.S.
NUZYRA Expected to be the First and Only Antibiotic to be Made in the U.S., Including API Production On-Shoring of NUZYRA Manufacturing 2021 2022 2023
Slide 22: Nuzyra Added to the FDA Essential Medicines List
Nuzyra Added to the FDA Essential Medicines List Important Biothreat Medical Counter Measure
Slide 23: NUZYRA: A Franchise Product
NUZYRA: A Franchise Product Paratek Pipeline *We have entered into a collaboration agreement with Zai Lab (Shanghai) Co., Ld., for the greater China region
Slide 24: NTM (M. abscessus) Opportunity
(1) Assumes 2028 NTM incidence of 72k, of which 9% is M. abscessus species. Strollo, “The Burden of Pulmonary NTM in the U.S.”, AnnalsATS Vol 12;10, 2015. Lee, “Mycobacterium abscessus Complex Infections in Humans”, EmergingInfDis, Vol 21;9, 2015. (2) Am J Respir Crit Care Med Vol 175. pp 367–416, 2
Slide 25: Phase 2b Study in NTM (M. abscessus)
Phase 2b Study in NTM (M. abscessus) Study Initiation Expected in 1H 2021 ~75 patients randomized 1.5:1 (OMC:PBO)
Slide 26: Robust Data Generation Underway for NUZYRA
Robust Data Generation Underway for NUZYRA Paratek’s Commitment to Scientific Exchange 19 Publications for NUZYRA Accepted in 2020 2: Reviews 8: Pathogens of interest 3: Pharmacokinetics and pharmacodynamics 1: Disease state outcomes CABP 5: Outcomes for NUZYRA for populations of interest 10 Inve
Slide 27: A New Resource for Healthcare Professionals
A New Resource for Healthcare Professionals Medical Affairs Website
Slide 28: NDA Submission of Omadacycline in China
New Drug Application (NDA) Submission of Omadacycline in China Priority Review Granted by the National Medical Products Administration Zai Lab announced priority review granted by NMPA in May 2020 Seeking approval for the treatment of CABP and ABSSSI; expected 1H 2021 In March 2020, Zai Lab entered
Slide 29: Questions & Answers
Questions & Answers GPARATEK
Slide 30: Closing Remarks
Closing Remarks Evan Loh, M.D. Chief Executive Officer
Slide 31: Disciplined Focus on Execution + Future Value Creation
Disciplined Focus on Execution + Future Value Creation Paratek is Well-Positioned for Long-Term Growth NUZYRA® 100mg for injection & 150mg tablets Near Term Execution Future Value Creation
Paratek Pharmaceuticals — FY2020 Earnings Presentation on 6ix